Echosens

Empowering medical professionals to assess, diagnose
and manage chronic liver diseases, everywhere, The examination is non-invasive, fast, and painless.

Echosens™, founded in 2001, is a French high-technology company specialising in non-invasive diagnostics for use in hepatology. Echosens™ is very active in research and development, and currently holds patents from 17 different fields, focusing mainly on its key technology: Vibration-Controlled Transient Elastography (VCTE™). n innovative technology: Vibration-Controlled Transient Elastography (VC

TE)

Echosens™ is the inventor of a highly innovative technology: pulse elastography. This has caused a fundamental change in the clinical practice of hepatologists. Echosens develops and markets the FibroScan®, a unique device for the diagnosis and monitoring of liver disease. With more than 660 publications, FibroScan® with its dedicated probes is the elastography device with by far the most evidence to demonstrate its clinical usefulness. The best-performing range of blood tests on the market

Applying the same philosophy, FibroMeter™ scores combine several biological markers to predict the presence of fibrosis in the liver. This complete range of blood scores, developed by Prof. Calès's team at the Angers teaching hospital in France, has given rise to the publication of many articles in world-class scientific journals, and is covered by a series of patents. Echosens™ devotes a significant proportion of its activity to research, with the aim of developing new medical devices and opening up new medical horizons. The company works in close collaboration with health professionals and patients' associations to facilitate the therapeutic monitoring of patients. To date, more than 2000 FibroScan® units have been installed all over the world. Structure

10/06/2026

We’ve reached an important milestone in the development of therapies for MASH (metabolic dysfunction-associated steatohepatitis).

Here’s what sets FibroScan® apart today:
🔹 FibroScan® is the only point of care non-invasive tool in the prescribing information label of MASH therapeutics
🔹 The FDA has approved Echosens’ Letter of Intent to qualify LSM by VCTE® (FibroScan®) as non-invasive surrogate endpoint in MASH clinical trials to replace biopsy

These milestones signal meaningful progress in both MASH therapeutics and clinical research, advancing the role of non-invasive tools for patients and providers.

👉 Together, we’re shaping the future of liver health in metabolic care.

Learn more about FibroScan®: https://www.echosens.com/fibroscan/

08/06/2026

🔔 Retrouvez-nous demain pour un webinaire en direct avec Dr. Emmanuelle Lecornet-Sokol et Dr. Olivier Dupuy.

✅ Pourquoi participer ?
🔹 Mieux comprendre les enjeux du dépistage de la MASLD/MASH chez les patients à risque
🔹Mettre en place un dépistage systématique en pratique libérale selon les recommandations
🔹Découvrir le rôle du FibroScan® dans la stratification du risque et le suivi
🔹S’approprier des cas concrets (diabète / obésité) applicables en pratique quotidienne

👉

mardi 09 juin 2026 à 18:30 Heure d'été d'Europe centrale. Comment dépister et prendre en charge les patients vivant avec un diabète de type 2 et/ou une obésité ? En France, la MASLD/MASH touche une proportion croissante de patients vivant avec un diabète de type 2 ou une obésité, avec un r...

05/06/2026

Our commitment to clinical evidence sets the standard for everything we build.
As June marks , it’s an important moment to highlight the role of innovation and evidence in advancing liver health worldwide.

Today, FibroScan® is supported by:
📄 6,270+ peer‑reviewed publications
🌍 250+ international guidelines

A global standard of care — built on science.

Access our webinar library for more clinical information: https://gateway.on24.com/wcc/eh/1905202/echosens-on-demand-clinical-webinar-library

Together, we’re shaping the future of liver health in metabolic care.

Swipe through our key milestones👇

04/06/2026

¡Esta noche! 📢 Webinar en directo - FibroScan® en el paciente hepatometabólico : Valor clínico y nuevas oportunidades en consulta privada, Presentado por Dr. Jose Altamirano y Dr. Julián Andrés Tamayo Serrato
📅 4 de junio · 19:30 CET
➡️ Inscripción abierta:

Thursday, June 04, 2026 at 7:30 PM Central European Summer Time. Hoy en día, los pacientes con diabetes tipo 2, obesidad y dislipemia representan una parte creciente de la consulta privada. Sin embargo, la enfermedad hepática metabólica (MASLD/MASH) y el papel central del hígado en el síndrome ...

01/06/2026

📰 A new clinical study is now available:

In the most recent AGA guidelines, LSM by VCTE® (FibroScan) has evolved from a secondary triage tool in older NAFLD algorithms to a central component of newer MASLD pathways.

Where it was once used mainly to clarify indeterminate FIB-4 results through simple cutoffs (12 kPa), it is now more tightly integrated into risk stratification, helping to reduce indeterminate cases and guide both MASH treatment initiation and monitoring 📊.

The updated guidelines also broaden its application: screening is now recommended for patients with obesity or overweight who have at least one additional cardiometabolic risk factor, and clinicians are encouraged to proceed directly with FibroScan®, bypassing FIB-4 in specialty or primary care settings where the technology is readily available, particularly in individuals with diabetes.

29/05/2026

For over 25 years, VCTE® has set the benchmark for non-invasive liver assessment.
To mark the 25th anniversary of Echosens, we’re taking a closer look at the science behind FibroScan®.

📘 Our new white paper, “The Technology Behind FibroScan® Explained,” explores the technological foundations of vibration-controlled transient elastography —its principles, controls, and the innovations that ensure reliable, standardized liver stiffness measurements worldwide.

Discover:
✅ Why FibroScan® remains the most trusted transient elastography device
✅ What differentiates it from other technologies
✅ How 25 years of innovation continue to serve clinical practice

👉 Download the white paper now: https://www.echosens.com/whitepaper2026/

27/05/2026

We’re live from in Barcelona! 🌍
Our team is on-site and ready to share our latest innovations in noninvasive liver care.

📍 Join us at booth C03 and don’t miss our key sessions:

🔬 Today | 17:00
Redefining Noninvasive Management of Advanced Liver Disease in the Baveno VIII Era

🧪 May 28 | 14:00
The Role of FibroScan® in Patient Selection and Treatment Monitoring in MASH

📊 May 29 | 14:00
Role of Liver Stiffness Measurement in Hepatocellular Carcinoma Risk Stratification

🤝 Whether you’re looking for insights, discussions, or live demonstrations — our team is here for you.

👉 Explore the full program: https://www.echosens.com/easl-2026/

22/05/2026

The countdown is on! ⏳
The kicks off next week in Barcelona and we can’t wait to connect with healthcare professionals from around the world.

📍 Meet us at booth C03 and dive into our scientific sessions:

🔬 May 27 | 17:00
Redefining Noninvasive Management of Advanced Liver Disease in the Baveno VIII Era

🧪 May 28 | 14:00
The Role of FibroScan® in Patient Selection and Treatment Monitoring in MASH

📊 May 29 | 14:00
Role of Liver Stiffness Measurement in Hepatocellular Carcinoma Risk Stratification

🎓 Skills Learning Center : Join our hands-on sessions (Room SLC1 Hall 7) on May 27 at 10:00, 13:30 and 16:15 👩‍⚕️👨‍⚕️
📍 Throughout the congress : Stop by the screening station outside the congress center, located at the North entrance

👉 Discover the full program here: https://www.echosens.com/easl-2026/

See you in Barcelona!

EASL - The Home of Hepatology

20/05/2026

For 25 years, innovation has been at the heart of Echosens.

Today, FibroScan® is:
✅ The preferred non-invasive tool, cited in major U.S. and European clinical practice guidelines, for assessing liver fibrosis and steatosis in patients with MASLD/MASH
✅ A globally recognized non-invasive solution trusted by clinicians in 127+ countries

Our commitment remains unchanged: innovating solutions that truly matter for patients.

👉 Together, we’re shaping the future of liver health in metabolic care.

Explore our clinical newsletters: https://www.echosens.com/clinical-evidences/clinical-enews/

19/05/2026

May 19th marks National Hepatitis Testing Day in the United States.

Millions of Americans are living with chronic viral hepatitis — a silent and often asymptomatic disease.
When left undiagnosed, hepatitis can lead to serious liver complications, including cirrhosis and liver cancer.

Testing is the only way to know your status ✅
On this day, we join the global effort to raise awareness and encourage hepatitis screening for earlier detection and better liver health.

Learn more 👉 https://www.echosens.com/viral-hepatitis/

Adresse

6 Rue Ferrus
Paris
75014

Téléphone

+33 1 44 82 78 50

Site Web

http://www.echosens.com/

Notifications

Soyez le premier à savoir et laissez-nous vous envoyer un courriel lorsque Echosens publie des nouvelles et des promotions. Votre adresse e-mail ne sera pas utilisée à d'autres fins, et vous pouvez vous désabonner à tout moment.